Maturitas
Volume 60, Issue 1 , Pages 59-64 , 20 May 2008

Risks of hormone therapy in the 50–59 year age group

Received 24 November 2007 ,Revised 9 April 2008 ,Accepted 14 April 2008.

References 

  1. Rossouw JE, Anderson GL, Prentice RL, et al. for the Writing Group for Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  3. The Women's Health Initiative Study Group. Design of the women's health initiative clinical trial and observational study. Cont Clin Trials. 1998;19:61–109
  4. Anderson GL, Limacher M, Assaf AR, et al. for the Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  5. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477
  6. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356:2591–2602
  7. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's health Initiative observational and clinical trial data on postmenpausal hormone therapy and cardiovascular disease. Am J Epidemiol. 2006;163:589–599
  8. Anderson Gl , Chlebowski RT, Rossouw JE, et al. Prior hormone hterapy and breastcancer risk in the Women's health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55:103–115
  9. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295:1647–1657
  10. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;291:1701–1712
  11. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Int Med. 2006;166:772–780
  12. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005;293:330–339
  13. Greiser CM, Greiser EB, Dören M. Menopausal hormone therapy and risk of ovarian cancer. Systematic review and meta-analysis. Hum Reprod Update. 2007;13:453–463
  14. Beral V, Bull D, Green J, et al. Million Women Study Collaborators Ovarian cancer and hormone replacement therapy in the million women study. Lancet. 2007;369:1703–1710
  15. Lacey JV, Brinton LA, Leitzmann MF. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Nat Cancer Inst. 2006;98:1397–1405
  16. Council for International Organizations of Medical Sciences (CIOMS) . Guidelines for preparing core clinical-safety information of drugs. 2nd ed.. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS); 1998;

PII: S0378-5122(08)00117-5

doi: 10.1016/j.maturitas.2008.04.010

Maturitas
Volume 60, Issue 1 , Pages 59-64 , 20 May 2008

Article Tools